comparemela.com

Latest Breaking News On - Diabetes mellitus type 2 - Page 6 : comparemela.com

Can Gut Microbiota Predict Multifactorial Disease Risk?

Research suggested that bacteria alone do not play an important role in determining disease risk.

Rocha fernandesDan linetzky waitzbergDanielle fonsecaFaculty of medicine the universityMedscape portugueseOint inflammationActerial infectionRheumatoid arthritis raHeumatoid arthritis raSystemic lupus erythematosus sle erythaematosusDiabetes mellitus type 2Iabetes mellitus type iiType 2 diabetesYpe 2 dmArtificial intelligenceDeep learning

Is Metformin a Drug for All Diseases ?

Metformin, a staple of glucose management for decades, is now being studied for use in a wide range of diseases from carotid atherosclerosis to vitiligo.

United statesNew yorkUnited kingdomRocky mountainGregoryg schwartzLakshay jainColumbia university irving medical centerDepartment of thoracic surgeryWorld health organizationUniversity of colorado school medicineMountain regional va medical centerAmerican diabetes associationDrug administrationBritish columbiaMedscape medicalRocky mountain regional

Can GLP-1 Agonists Reduce Risk for Severe Liver Disease?

GLP-1 agonists could be a treatment option to reduce the risk for major adverse liver outcomes in adults with type 2 diabetes and chronic liver disease.

United statesKarolinska institutetAxel westerJamile wakim flemingDepartment of medicineMedscape medicalMetabolic steatosisCleveland clinicDiabetes mellitus type 2Iabetes mellitus type iiType 2 diabetesYpe 2 dmBiliary diseaseAllbladder diseaseLiver diseaseHepatic impairment

Diabetic Kidney Disease Deaths Rising in Latin America

The phenomenon is believed to result from difficulties in accessing quality healthcare, as indicated in a recent study.

La plataBuenos airesNuevo leóxUnited statesLilia rizoChristus muguerza alta especialidadCarmen antini irribarraNational university of la plataWorld health organization globalWorld health organization global diabetes compactMexican council of nephrologyInternational journal of epidemiologyPan american health organizationUniversity of monterreyLatin americanInternational journal

Empagliflozin Sheds Liver Fat in People With and Without T2D

Empagliflozin reduced liver fat content in patients with obesity and patients with type 2 diabetes.

San antonioUnited statesUniversity of texasSiham abdelganiDivision of diabetesUniversity of texas health science centerTexas health science centerLiver diseaseHepatic impairmentDiabetes mellitus type 2Iabetes mellitus type iiType 2 diabetesYpe 2 dm

vimarsana © 2020. All Rights Reserved.